Literature DB >> 9190286

Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.

J D Harper1, S S Wong, C M Lieber, P T Lansbury.   

Abstract

BACKGROUND: Brain amyloid plaque, a diagnostic feature of Alzheimer's disease (AD), contains an insoluble fibrillar core that is composed primarily of variants of the beta-amyloid protein (Abeta). As Abeta amyloid fibrils may initiate neurodegeneration, the inhibition of fibril formation is a possible therapeutic strategy. Very little is known about the early steps of the process, however.
RESULTS: Atomic force microscopy was used to follow amyloid fibril formation in vitro by the Abeta variants Abeta1-40 and Abeta1-42. Both variants first form small ordered aggregates that grow slowly and then rapidly disappear, while prototypical amyloid fibrils of two discrete morphologies appear. Abeta1-42 aggregates much more rapidly than Abeta1-40, which is consistent with its connection to early-onset AD. We propose that the metastable intermediate species be called Abeta amyloid protofibrils.
CONCLUSIONS: Abeta protofibrils are likely to be intermediates in the in vitro assembly of Abeta amyloid fibrils, but their in vivo role has yet to be determined. Numerous reports of a nonfibrillar form of Abeta aggregate in the brains of individuals who are predisposed to AD suggest the existence of a precursor form, possibly the protofibril. Thus, stabilization of Abeta protofibrils may be a useful therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9190286     DOI: 10.1016/s1074-5521(97)90255-6

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  185 in total

1.  Molecular modelling indicates that the pathological conformations of prion proteins might be beta-helical.

Authors:  D T Downing; N D Lazo
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

2.  Conformational propagation with prion-like characteristics in a simple model of protein folding.

Authors:  P M Harrison; H S Chan; S B Prusiner; F E Cohen
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

Review 3.  Amyloid diseases: abnormal protein aggregation in neurodegeneration.

Authors:  E H Koo; P T Lansbury; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

4.  De novo amyloid proteins from designed combinatorial libraries.

Authors:  M W West; W Wang; J Patterson; J D Mancias; J R Beasley; M H Hecht
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption.

Authors:  C M Yip; J McLaurin
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

Review 6.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease.

Authors:  P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  Ultrastructural organization of amyloid fibrils by atomic force microscopy.

Authors:  A K Chamberlain; C E MacPhee; J Zurdo; L A Morozova-Roche; H A Hill; C M Dobson; J J Davis
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

8.  Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation.

Authors:  Melanie R Nilsson; Miles Driscoll; Daniel P Raleigh
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

9.  Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy.

Authors:  C Ionescu-Zanetti; R Khurana; J R Gillespie; J S Petrick; L C Trabachino; L J Minert; S A Carter; A L Fink
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 10.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.

Authors:  Dennis J Selkoe
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.